GLP-1– tag –
-
Boehringer Ingelheim Initiates Phase II Trial for BI 3034701, a Potential First-in-Class Triple Receptor Agonist for Obesity
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has launched a Phase II clinical trial for BI 3034701, an investigational triple GLP-1/GIP/NPY2 receptor agonist targeting patients with obesity and overweight. This molecule rep... -
Oral GLP-1 Market Shift: Foundayo (orforglipron) Gains FDA Approval After Oral Wegovy, Demonstrating Dosing Convenience Advantage
GoodRx Health USA Overview The oral GLP-1 receptor agonist market sees a new entrant as Foundayo (orforglipron) received FDA approval on April 1, 2026, becoming the second oral GLP-1 therapy after oral Wegovy (semaglutide). Foundayo offe... -
Obesity Treatment Advances: Foundayo and Oral Wegovy Lead Oral GLP-1 Market, Retatrutide Shows Significant Weight Loss in Phase II
GoodRx Health USA Overview The obesity therapeutics market is rapidly evolving, with Foundayo (orforglipron) and oral Wegovy driving the oral GLP-1 segment. Foundayo, FDA-approved on April 1, 2026, offers the novel advantage of being tak... -
Boehringer Ingelheim’s First-in-Class Obesity Drug BI 3034701 Enters Phase II, Triggers €10M Milestone Payment to Gubra
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has initiated a Phase II clinical trial for BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist for patients with obesity and overweight. This investiga... -
Eli Lilly’s Foundayo (orforglipron) Receives FDA Approval, Ushering in a New Era of Oral GLP-1 RAs for Obesity Treatment
2 Minute Medicine USA Overview On April 1, 2026, Eli Lilly's Foundayo (orforglipron) gained FDA approval for obesity treatment, marking the first non-peptide oral GLP-1 receptor agonist without food or water timing restrictions. This bre... -
Boehringer Ingelheim Announces Promising Interim Phase 2 Results for Obesity Treatment BI 3034701: A Potential First-in-Class Triple Receptor Agonist
Boehringer Ingelheim Germany Overview Boehringer Ingelheim announced promising interim results from its Phase 2 clinical trial for BI 3034701, a novel triple receptor agonist for obesity. BI 3034701, targeting GLP-1, GCG, and GIP recepto... -
2026 GLP-1 Agonist Pipeline Highlights Oral Orforglipron Approval and Retatrutide’s >28% Weight Reduction
Drug Discovery News USA Overview The 2026 GLP-1 agonist clinical pipeline is focusing on enhanced weight loss efficacy through novel mechanisms. Notably, Eli Lilly's oral small-molecule GLP-1 receptor agonist, orforglipron, received FDA ... -
The Rise of Oral GLP-1 Receptor Agonists: Transforming Diabetes and Obesity Treatment Convenience from Injections to Pills
Pharmacy Times USA Overview The advent of oral GLP-1 receptor agonists (GLP-1RAs) is fundamentally transforming drug administration in diabetes and obesity treatment. Oral formulations are rapidly gaining traction in the previously injec... -
GLP-1 Receptor Agonists Expand Therapeutic Scope to MASH: Novo Nordisk’s Wegovy First FDA-Approved for MASH, Eli Lilly’s Oral Foundayo Launched
Drug Discovery Trends USA Overview The therapeutic scope of GLP-1 receptor agonists has expanded beyond diabetes and obesity to include cardiovascular risk, obstructive sleep apnea, chronic kidney disease, and by 2025, MASH (Metabolic Dy... -
Oral GLP-1 Agonist Semaglutide Success Drives Peptide Drug Discovery Transformation: AI Design, Unnatural Amino Acids, and Nanocarriers Enhance Oral Bioavailability
Bhunia Lab Unknown Overview While peptide therapeutics have advanced significantly, oral delivery remains a challenge. The success of oral semaglutide demonstrates how chemical modifications like amino acid substitutions and fatty acid a...
